Healthcare provider profile · identity verified

Malvika Suri, MD

Internal Medicine · CARMICHAEL, CA · NPI 1598875346

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	487	164
Levothyroxine Sodium	Levothyroxine Sodium	391	116
Amlodipine Besylate	Amlodipine Besylate	338	121
Lisinopril	Lisinopril	266	88
Losartan Potassium	Losartan Potassium	261	88
Metoprolol Succinate	Metoprolol Succinate	160	60
Gabapentin	Gabapentin	149	63
Omeprazole	Omeprazole	145	60
Metformin Hcl Er	Metformin Hcl	141	56
Ozempic	Semaglutide	127	21
Simvastatin	Simvastatin	122	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	117	26
Tamsulosin Hcl	Tamsulosin Hcl	116	45
Famotidine	Famotidine	112	42
Trazodone Hcl	Trazodone Hcl	112	44
Albuterol Sulfate Hfa	Albuterol Sulfate	109	77
Metoprolol Tartrate	Metoprolol Tartrate	108	35
Hydrochlorothiazide	Hydrochlorothiazide	98	36
Pantoprazole Sodium	Pantoprazole Sodium	98	42
Temazepam	Temazepam	95	12
Fluticasone Propionate	Fluticasone Propionate	94	38
Atenolol	Atenolol	93	31
Alendronate Sodium	Alendronate Sodium	88	33
Furosemide	Furosemide	87	41
Carvedilol	Carvedilol	84	27
Duloxetine Hcl	Duloxetine Hcl	81	35
Rosuvastatin Calcium	Rosuvastatin Calcium	72	24
Lovastatin	Lovastatin	69	21
Sertraline Hcl	Sertraline Hcl	67	23
Meloxicam	Meloxicam	59	20
Fluoxetine Hcl	Fluoxetine Hcl	57	20
Potassium Chloride	Potassium Chloride	57	23
Ibuprofen	Ibuprofen	56	27
Pradaxa	Dabigatran Etexilate Mesylate	56	21
Azelastine Hcl	Azelastine Hcl	55	20
Donepezil Hcl	Donepezil Hcl	55	18
Montelukast Sodium	Montelukast Sodium	55	17
Jardiance	Empagliflozin	53	21
Clopidogrel	Clopidogrel Bisulfate	49	16
Tizanidine Hcl	Tizanidine Hcl	49	18
Paxlovid	Nirmatrelvir/Ritonavir	48	48
Allopurinol	Allopurinol	47	17
Cefadroxil	Cefadroxil	46	40
Hydralazine Hcl	Hydralazine Hcl	44	17
Alprazolam	Alprazolam	43	suppressed
Ondansetron Hcl	Ondansetron Hcl	43	13
Terazosin Hcl	Terazosin Hcl	41	12
Wixela Inhub	Fluticasone Propion/Salmeterol	41	15
Tramadol Hcl	Tramadol Hcl	40	11
Escitalopram Oxalate	Escitalopram Oxalate	39	15
Spironolactone	Spironolactone	38	14
Alvesco	Ciclesonide	37	26
Spiriva Respimat	Tiotropium Bromide	37	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	36	suppressed
Clobetasol Propionate	Clobetasol Propionate	35	18
Glipizide	Glipizide	35	14
Triamcinolone Acetonide	Triamcinolone Acetonide	35	25
Acyclovir	Acyclovir	34	14
Baclofen	Baclofen	34	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	34	32
Citalopram Hbr	Citalopram Hydrobromide	33	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	12
Warfarin Sodium	Warfarin Sodium	31	14
Metronidazole	Metronidazole	29	19
Chlorthalidone	Chlorthalidone	28	suppressed
Amoxicillin	Amoxicillin	27	22
Humulin N	Insulin Nph Human Isophane	27	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	23
Oxycodone Hcl	Oxycodone Hcl	27	suppressed
Prednisone	Prednisone	27	22
Propranolol Hcl	Propranolol Hcl	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Humulin R	Insulin Regular, Human	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Breyna	Budesonide/Formoterol Fumarate	22	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	suppressed
Finasteride	Finasteride	21	suppressed
Nystatin	Nystatin	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	20
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	20	20
Azithromycin	Azithromycin	20	20
Buprenorphine	Buprenorphine	20	suppressed
Celecoxib	Celecoxib	20	suppressed
Cephalexin	Cephalexin	20	16
Eliquis	Apixaban	20	suppressed
Metformin Hcl	Metformin Hcl	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	16	16
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Fluocinonide	Fluocinonide	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Fenofibrate	Fenofibrate	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Colchicine	Colchicine	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Epinephrine	Epinephrine	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Retin-A	Tretinoin	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error